Detalhe da pesquisa
1.
Pityriasis Rubra Pilaris: A Multicentric Case Series of 65 Spanish Patients.
Actas Dermosifiliogr
; 2024 Feb 22.
Artigo
em Inglês, Espanhol
| MEDLINE | ID: mdl-38401879
2.
Pharmacogenetic biomarkers for secukinumab response in psoriasis patients in real-life clinical practice.
J Eur Acad Dermatol Venereol
; 2023 Dec 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-38153843
3.
Moderate to Severe Psoriasis in Pediatric and Young Patients: The BIOBADADERM Registry Experience. / Psoriasis moderada-grave en pacientes pediátricos y jóvenes: experiencia en el registro BIOBADADERM.
Actas Dermosifiliogr
; 113(4): 401-406, 2022 Apr.
Artigo
em Inglês, Espanhol
| MEDLINE | ID: mdl-35428502
4.
Real-world effectiveness and safety of apremilast in psoriasis at 52 weeks: a retrospective, observational, multicentre study by the Spanish Psoriasis Group.
J Eur Acad Dermatol Venereol
; 34(12): 2821-2829, 2020 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-32271966
5.
Initial results of ixekizumab efficacy and safety in real-world plaque psoriasis patients: a multicentre retrospective study.
J Eur Acad Dermatol Venereol
; 33(3): 553-559, 2019 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-30317679
6.
Active tuberculosis in a cohort of patients with psoriasis on biologic therapy: learnings from real-life medical practice.
J Eur Acad Dermatol Venereol
; 36(9): e689-e691, 2022 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-35398915
7.
Women with moderate-to-severe psoriasis in Spain (BIOBADADERM registry) breastfeed less when compared with general population.
J Eur Acad Dermatol Venereol
; 36(3): e205-e207, 2022 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-34626521
8.
Comparison of phenotype, comorbidities, therapy and adverse events between psoriatic patients with and without psoriatic arthritis. Biobadaderm registry.
J Eur Acad Dermatol Venereol
; 31(6): 1021-1028, 2017 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-28252811
9.
Adverse events associated with discontinuation of the biologics/classic systemic treatments for moderate-to-severe plaque psoriasis: data from the Spanish Biologics Registry, Biobadaderm.
J Eur Acad Dermatol Venereol
; 31(10): 1700-1708, 2017 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-28485816
10.
Oral health and systemic inflammatory, cardiac and nitroxid biomarkers in hemodialysis patients.
Med Oral Patol Oral Cir Bucal
; 22(4): e432-e439, 2017 Jul 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28578371
11.
Management of Biologic Therapy in Moderate to Severe Psoriasis in Surgical Patients: Data From the Spanish Biobadaderm Registry. / Manejo de los tratamientos biológicos en pacientes con psoriasis moderada-grave sometidos a intervenciones quirúrgicas en el registro español Biobadaderm.
Actas Dermosifiliogr
; 108(1): 52-58, 2017.
Artigo
em Inglês, Espanhol
| MEDLINE | ID: mdl-27658689
12.
Maintenance of response following discontinuation of guselkumab and secukinumab in Spanish patients who participated in the ECLIPSE study.
J Eur Acad Dermatol Venereol
; 35(1): e65-e67, 2021 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-32648955
13.
Survival of classic and biological systemic drugs in psoriasis: results of the BIOBADADERM registry and critical analysis.
J Eur Acad Dermatol Venereol
; 30(11): 1942-1950, 2016 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-27329511
14.
Use of biological treatments in patients with hidradenitis suppurativa.
J Eur Acad Dermatol Venereol
; 29(1): 56-60, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24629001
15.
Safety of classic and biologic systemic therapies for the treatment of psoriasis in elderly: an observational study from national BIOBADADERM registry.
J Eur Acad Dermatol Venereol
; 29(5): 858-64, 2015 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-25185962
16.
Risk of adverse events in psoriasis patients receiving classic systemic drugs and biologics in a 5-year observational study of clinical practice: 2008-2013 results of the Biobadaderm registry.
J Eur Acad Dermatol Venereol
; 29(1): 156-63, 2015 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24684267
17.
Immune-mediated inflammatory diseases and other comorbidities in patients with psoriasis: baseline characteristics of patients in the AQUILES study.
Actas Dermosifiliogr
; 106(1): 35-43, 2015.
Artigo
em Inglês, Espanhol
| MEDLINE | ID: mdl-25091923
18.
Does the treatment ladder for systemic therapy in moderate to severe psoriasis only go up? The percentage of patients with severe psoriasis on biologics increases over time.
Actas Dermosifiliogr
; 106(8): 638-43, 2015 Oct.
Artigo
em Inglês, Espanhol
| MEDLINE | ID: mdl-26141003
19.
Women with moderate-to-severe psoriasis in Spain (BIOBADADERM registry) show more than a 50% reduction in age-adjusted fertility rate when compared with the general population.
Br J Dermatol
; 181(5): 1085-1087, 2019 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-31127858
20.
Body mass index in patients with moderate-to-severe psoriasis in Spain and its impact as an independent risk factor for therapy withdrawal: results of the Biobadaderm Registry.
J Eur Acad Dermatol Venereol
; 28(7): 907-14, 2014 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-23848131